Aquestive Therapeutics, Inc. (AQST) vs Immix Biopharma, Inc. (IMMX)

A side-by-side comparison of Aquestive Therapeutics, Inc. and Immix Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AQST

Aquestive Therapeutics, Inc.

$577M

$4.60HealthcareDelayed quote: Oct 6, 2026, 11:35 AM EDT

IMMX

Immix Biopharma, Inc.

$541M

$9.95HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT

Total return — AQST vs IMMX

growth of $100 · dividends reinvested · last 5y

AQST -13.0% (-2.7%/yr)IMMX +176.0% (+22.5%/yr)IMMX compounded faster over this window

AQST IMMX

AQST vs IMMX: by the numbers

•AQST is the larger company ($577M vs $541M market cap).
•Both run net losses; IMMX's is the smaller (0.00% vs -144.63% net margin).

Metrics side by side

Valuation

Metric	AQST	IMMX
P/S ratio	10.66	N/A
P/B ratio	N/A	2.36

Profitability

Metric	AQST	IMMX
Gross margin	67.04%	0.00%
Operating margin	-156.36%	0.00%
Net margin	-144.63%	0.00%
ROE	N/A	-17.44%
ROIC	-45.62%	-18.20%

Growth (annualized)

Metric	AQST	IMMX
Revenue CAGR (5Y)	-0.58%	N/A
Total return CAGR (5Y)	2.24%	N/A

Go deeper

Full AQST analysis Full IMMX analysis Interactive comparison tool

Dig into the metrics

Aquestive Therapeutics ROE Immix Biopharma ROE Aquestive Therapeutics operating margin Immix Biopharma operating margin Aquestive Therapeutics revenue growth Immix Biopharma revenue growth Aquestive Therapeutics free cash flow Immix Biopharma free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.